Journal
ALLERGY
Volume 74, Issue 11, Pages 2157-2166Publisher
WILEY
DOI: 10.1111/all.13867
Keywords
chemokines; immunotherapy and tolerance induction; immunotherapy vaccines and mechanisms; T cells; vaccines
Categories
Funding
- NIAID NIH HHS [U19 AI100266] Funding Source: Medline
- Pharmaceuticals [CP003] Funding Source: Medline
Ask authors/readers for more resources
Background Allergen immunotherapy using synthetic peptide T-cell epitopes (Cat-PAD) from the major cat allergen Fel d 1 has been shown, in allergen exposure studies, to significantly reduce symptoms of allergic rhinoconjunctivitis in cat-allergic subjects. However, the immunological mechanisms underlying clinical benefit remain only partially understood. Since previous studies of whole allergen immunotherapy demonstrated a reduction in the frequency of allergen-specific (MHC II tetramer(+)) CD4(+) T cells expressing the chemokine receptor CRTh2, we assessed the impact of Cat-PAD on the frequency and functional phenotype of Fel d 1-specific CD4(+) T cells. Methods Using before and after treatment samples from subjects enrolled in a randomized, double-blind, placebo-controlled trial of Cat-PAD, we employed Fel d 1 MHC II tetramers and flow cytometry to analyze the expression of chemokine receptors CCR3, CCR4, CCR5, CXCR3, and CRTh2, together with markers of memory phenotype (CD27 and CCR7) on Fel d 1-specific CD4(+) T cells. Results No statistically significant change in the frequency of Fel d 1-specific CD4(+) T cells, nor in their expression of chemokine receptors or memory phenotype, was observed. However, a significant reduction in cell surface expression of CRTh2 was observed between the placebo and active groups (P = 0.047). Conclusions Peptide immunotherapy with Cat-PAD does not significantly alter the frequency or phenotype of Fel d 1-CD4(+) T cells, but may decrease their expression of CRTh2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available